TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Consensus Rating of "Buy" by Analysts

Key Points

• TuHURA Biosciences, Inc. (NASDAQ:HURA) has received an average recommendation of "Buy" from analysts, with three firms rating it as a buy and two as strong buy.
• The company's average 1-year price target is $12.67, despite recent stock prices hovering around $2.55.
• In its latest quarterly earnings report, TuHURA missed analysts' expectations with a reported loss of ($0.21) EPS versus the consensus of ($0.14).

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five brokerages that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.6667.

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $12.00 target price on shares of TuHURA Biosciences in a report on Friday, May 16th. Brookline Capital Management raised TuHURA Biosciences to a "strong-buy" rating in a research report on Monday, June 23rd. Finally, Wall Street Zen lowered TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 30th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new stake in shares of TuHURA Biosciences in the 2nd quarter worth about $27,000. Intech Investment Management LLC bought a new position in TuHURA Biosciences in the second quarter worth about $29,000. Invesco Ltd. purchased a new stake in TuHURA Biosciences in the second quarter worth about $30,000. Merck & Co. Inc. bought a new stake in TuHURA Biosciences during the 2nd quarter valued at approximately $31,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of TuHURA Biosciences during the 2nd quarter worth approximately $31,000. 0.62% of the stock is currently owned by institutional investors.

TuHURA Biosciences Stock Up 9.3%

Shares of TuHURA Biosciences stock traded up $0.22 on Friday, hitting $2.59. The stock had a trading volume of 280,368 shares, compared to its average volume of 280,015. TuHURA Biosciences has a one year low of $1.80 and a one year high of $8.40. The stock's 50-day simple moving average is $2.67 and its two-hundred day simple moving average is $3.01.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.07).

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.